Anti-Dengue Virus Type IV Antibody, clone 1H10-6

Genome polyprotein (UniProt: Q58HT7; also known as Capsid protein C, Core protein Protein prM, Peptide pr, Small envelope protein M, Matrix protein, Envelope protein E) is encoded by the POLY gene (Gene ID: 5075729) in Dengue virus type 4 (strain Philippines/H241/1956) (DENV-4). Dengue fever is an acute, mosquito-transmitted viral disease characterized by fever, headache, arthralgia (severe retro-orbital pain), myalgia, rash, nausea, and vomiting. Infections are caused by any of the four closely related, but antigenically distinct virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). Infection with one of these serotypes does not provide cross-protective immunity, so persons living in a dengue-endemic area can have four dengue infections during their lifetimes. Dengue is primarily an urban disease of the tropics, and the viruses that cause it are maintained in a cycle that involves humans and Aedes aegypti, a domestic, day-biting mosquito that prefers to feed on humans. Although most dengue infections result in relatively mild illness, some can produce Dengue Hemorrhagic Fever (DHF) or dengue shock syndrome, with children being particularly at risk. Although epidemic outbreaks have been reported since 1779, the incidence has been increasing, with global, multiple serotype pandemics intensifying within the last 15 years. There is no specific antiviral therapy for dengue, but for both classical dengue and dengue hemorrhagic fever, symptomatic and supportive measures are effective. Important risk factors for DHF include the strain and serotype of the virus involved, as well as the age, immune status, and genetic predisposition of the patient.

Whole virus/Dengue type 4 virus antigens (H241).

Quality Control Testing

Evaluated by ELISA with Dengue Virus Type IV Virus Like Particles (VLPs).

Enzyme Immunoassay: A representative lot of this antibody detected Dengue Virus Type IV Virus Like Particles (VLPs) in ELISA application.

Tested Applications

Enzyme Immunoassay Analysis: A representative lot detected Dengue Virus Type IV in ELISA application (Antunez, M., et al., (2000), Rev. Cubana Med. Trop, 52(2), 119-125; Holman, D., et al., (2007), Clin. Vaccine. Immunol., 14(2), 182-189).

Neutralizing Assay: A representative lot neutralized activity of Dengue Virus Type IV in Neutralizing application (Sukupolvi-Petty, S., et al., (2013), J. Virol., 87(16), 8826-8842).

Western Blotting Analysis: A representative lot detected Dengue Virus Type IV in Western Blotting application (Holman, D., et al., (2007), Clin. Vaccine. Immunol., 14(2), 182-189).

Immunofluorescence Analysis: A representative lot detected Dengue Virus Type IV in Immunofluorescence application (Henchal, E., et al., (1982), Am. J. Trop. Med. Hyg, 31(4), 830-836; Antunez, M., et al., (2000), Rev. Cubana Med. Trop, 52(2), 119-125; Holman, D., et al., (2007), Clin. Vaccine. Immunol., 14(2), 182-189).

These cited applications are for the ascites version of this clone.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 1H10-6 is a mouse monoclonal antibody that detects Dengue Virus Type IV.

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

1.0 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommended storage: +2°C to +8°C.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.